RxDoctor Payments Data

Stephen Maynard

Family · Vero Beach, FLNPI 1104277649

Payments from drug & device makers

$1,257in general payments, 2019–2025

Across 48 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$710
  • Axonics, Inc.$131
  • Biohaven Pharmaceutical Holding Company Ltd.$122
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$76
  • GSK$46
  • Pfizer$46
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$1,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,257 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$148
Medicare patients
16
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide11$10,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,237
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$942
Albuterol Sulfate HfaAlbuterol Sulfate43$899
Gabapentin34$888
Atorvastatin Calcium57$348
Levothyroxine Sodium44$340
Losartan Potassium60$296
Rosuvastatin Calcium19$292
Metformin Hcl58$242
Amlodipine Besylate44$229
Lisinopril27$220
Potassium Chloride23$206
Pantoprazole Sodium20$203
Famotidine11$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$46$9,23714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →